PATH, WaterAid America report that diarrheal disease is overlooked
WASHINGTON PATH and WaterAid America released two reports Tuesday finding that the international aid community and developing-country governments are not targeting diarrheal disease, a leading killer of children under age 5 worldwide that is responsible for the deaths of nearly 1.6 million children annually.
“The global health community knows what is necessary to save the lives of children suffering from diarrheal disease,” stated John Wecker, director of the Immunization Solutions and Rotavirus Vaccine Program at PATH. “And now is the time to educate policymakers, donors and international and national leaders about the need to implement the solutions to prevent and treat the most severe causes.”
According to the reporters, there are more lifesaving prevention and treatment solutions for diarrheal disease than any other major childhood killer, including safe water; improved sanitation and hygiene; breastfeeding and optimal complementary feeding; rotavirus vaccines; zinc treatment; and oral rehydration therapy/oral rehydration solution.
The reports coincide with a World Health Organization review of data from studies of vaccines to prevent rotavirus — a common and lethal diarrheal disease — from clinical trials in Africa and Asia. The WHO will consider a global recommendation that every country introduce rotavirus vaccines into its routine immunization schedule based on this data.
“While diarrheal disease is a global killer, today the burden is greatest in developing nations in Africa and Asia where access to clean water, sanitation, and urgent medical care may be limited,” stated Nancy Bwalya-Mukumbuta, program manager at WaterAid in Zambia. “The international aid system and developing-country governments need to come together with a strong voice and respond to diarrheal disease, one of the leading causes of child mortality, in a targeted manner.”
Bausch & Lomb appoints new VP and global president, vision care
ROCHESTER, N.Y. Bausch & Lomb on Monday named Peter Valenti corporate VP and global president, vision care, effective July 1.
Valenti replaces Stuart Heap, who has chosen to step down from his current role with B&L for personal reasons, effective June 30. Heap will remain an active strategic advisor to the company.
“[Valenti] possesses a mix of deep leadership experience, healthcare and eye health expertise, and has already made significant contributions to helping grow the B&L business during his brief tenure,” stated Gerald Ostrov, B&L chairman and CEO. “At the same time, we thank [Heap] for his significant contributions to the company as he chooses to spend more time with his family.”
Valenti joined B&L in January 2009 as president, North America, vision care. Before being named to that role, Valenti served as VP and GM, surgical devices (U.S.), for Covidien, where he led the U.S. sales and marketing strategy for the $1 billion product portfolio from 2007 to 2008.
In conjunction with Valenti’s transition to his new role, the company has named Steven Robins as president, North America, vision care.
Robins joins B&L with approximately two decades of consumer healthcare experience at leading companies such as Johnson & Johnson, Pfizer and Warner Lambert. Most recently, he was GM, Johnson & Johnson Consumer Healthcare Canada, and a VP of the Johnson & Johnson Consumer Group, with responsibility for a number of health and beauty brands such as Listerine, Reach, Band-Aid, Stayfree and Purell.
Herb works as anti-ulcer therapy, study shows
BEIJING A research team led by Syed Rafatullah from Saudi Arabia validated the gastric anti-ulcer properties of the herb Rocket “Eruca sativa L.” (EER) on experimentally-induced gastric secretion and ulceration in albino rats. The study was published April 28 in the World Journal of Gastroenterology.
In recent years, Rocket “Eruca sativa L.” (EER), a member of the Brassicacae family, has gained greater importance as a salad vegetable and spice, especially among Middle Eastern populations and Europeans. It is believed that plants belonging to the Brassicacae family possess diversified medicinal and therapeutic properties including inhibition of tumorigenesis, anti-ulcer and hepatoprotective activities.
Although the introduction of proton-pump inhibitors to the classic anti-ulcer therapy has revolutionized treatment of peptic ulcers and other gastrointestinal disorders, there is still no complete cure for this disease, researchers noted. It has been shown that long term use of these drugs leads to various adverse and side effects. Relapses of the malady, ineffectiveness of different drug regimens and even resistance to drugs are emerging. Thus, there is an urgent requirement to identify more effective and safe anti-ulcer agents.
Researchers found that the ethanolic extract of EER significantly and dose-dependently reduced basal gastric acid secretion, titratable acidity and ruminal ulceration in lab rats. The authors concluded that EER extract possesses anti-ulcer activities against experimentally-induced gastric lesions.